CS patients with TRG3 tumours demonstrated a trend towards higher mortality risk when compared to CS patients with TRG1‐2 tumours; however, this did not achieve statistical significance (HR = 1.43, 95% CI = 0.694–2.958, P = 0.33). The gene discussed is SAMM50; the disease is neoplasm.